Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review-Reference-Cited by-同舟云学术

Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review

Published:2011-03-06 Issue:2 Volume:29 Page:704-706
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Kaidar-Person Orit,Billan Salem,Kuten Abraham

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-011-9884-1.pdf

Reference15 articles.

1. Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.

2. Press MF, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 1994;54:5675–82.

3. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006;24:2673–8.

4. Glisson B, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004;10:944–6.

5. Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck. 2007;29:907–11.

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunoprofiles and Oncologic Outcomes of 15 Patients with Androgen Receptor-Positive Salivary Duct Carcinoma;Cancers;2024-03-19

2. HER2-targeted therapies for salivary gland cancers;Oral Oncology;2024-01

3. Systemic therapies for salivary gland carcinoma (excluding adenoid cystic carcinoma): REFCOR recommendations by the formal consensus method;European Annals of Otorhinolaryngology, Head and Neck Diseases;2023-11

4. Carcinoma ex pleomorphic adenoma in an elderly patient: A case report and literature review;Oral and Maxillofacial Surgery Cases;2022-09

5. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing;Modern Pathology;2021-12-28